ロード中...
FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation
Tyrosine kinase inhibitors (TKIs) targeting FLT3 have shown activity but when used alone have achieved limited success in clinical trials, suggesting the need for combination with other drugs. We investigated the combination of FLT3 TKIs (Gilteritinib or Sorafenib), with Venetoclax, a BCL-2 selectiv...
保存先:
| 出版年: | Signal Transduct Target Ther |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Nature Publishing Group UK
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8141515/ https://ncbi.nlm.nih.gov/pubmed/34024909 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41392-021-00578-4 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|